Biogen’s Fampyra Awarded Standard Marketing Authorization in EU

May 29, 2017

The European Commission has granted a standard marketing authorization for Fampyra for walking improvement in multiple sclerosis patients.

The full clearance was based on the results of a Phase 3 clinical study conducted following the EC’s conditional marketing authorization for Fampyra in 2011.

Biogen has a license from Acorda Therapeutics to commercialize Fampyra in markets outside the United States.

View today's stories